UPB
Upstream Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.80
+1.45%Year over year
Reported trailing growth
- Revenue
- +16.0%
- EBITDA
- -39.2%
- EBIT
- -39.8%
- EPS
- -40.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -44.8%
- EBITDA
- -1.3%
- EPS
- -0.2%
Three-year CAGR
- Revenue
- +33.0%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- -78.5%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026